<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903601</url>
  </required_header>
  <id_info>
    <org_study_id>DSRiK/10/2019</org_study_id>
    <nct_id>NCT03903601</nct_id>
  </id_info>
  <brief_title>Concentration of Trimethylamine Oxide (TMAO) in Blood Plasma as a Risk Factor for Vascular Cerebral Damage</brief_title>
  <official_title>Concentration of Trimethylamine Oxide (TMAO) in Blood Plasma as a Risk Factor for Vascular Cerebral Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gdansk University of Physical Education and Sport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gdansk University of Physical Education and Sport</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the current research project is to answer the question, whether plasma
      trimethylamine N-oxide (TMAO) level may be used as a marker of ischemic changes in the brain.
      TMAO is associated with endothelial dysfunction, inflammation and oxidative stress.

      The hypothesis is that circulating TMAO level may predict leukoaraiosis (LA) and/or stroke.

      Secondary, the investigators would like to examine whether plasma TMAO concentration is
      related to cognitive impairment and determine whether choline consumption is associated with
      an incidence of LA severity and dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study, subjects will be recruited in the hospital among the patients with brain MRI
      performed within past 4 weeks. All MRI scans will be reviewed by the neurologist to evaluate
      ischemic changes. Upon detection of LA, patients (n=150) will be informed about the study
      aims. In the same time, aged- and sex-matched control group (n=150) with no detected ischemic
      changes will be recruited.

      In each group, the blood samples will be collected, to determine the concentration of plasma
      TMAO, oxidative stress markers, as well as serum endothelial dysfunction markers and
      biochemical parameters. To determine the cognitive performance psychological test will be
      carried out. The diet of all recruited participants, with special consideration on the
      choline-rich products and supplements, will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>before qualifying for the study, during the recruitment period</time_frame>
    <description>Leukoaraiosis severity will be evaluated in MRI scans according to the Fazekas' scale. Will be grading scale for periventricular hyperintensities (PVH) and scale of deep white matter hyperintensities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trimethylamine-N-oxide (TMAO) blood concentration</measure>
    <time_frame>up to 4 weeks after brain MRI</time_frame>
    <description>TMAO concentration determined by the ultra-performance liquid-chromatography tandem mass spectrometry (UPLC-MS/MS), marked in Âµmol/l.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF)</measure>
    <time_frame>up to 4 weeks after brain MRI</time_frame>
    <description>BDNF concentration determined in serum by ELISA method, marked in pg/mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>up to 4 weeks after brain MRI</time_frame>
    <description>MMSE is a screening tool for cognitive functions impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test (TMT)</measure>
    <time_frame>up to 4 weeks after brain MRI</time_frame>
    <description>TMT test to determine the executive functions.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vascular Diseases</condition>
  <condition>Leukoaraiosis</condition>
  <condition>Ischemia, Cerebral</condition>
  <arm_group>
    <arm_group_label>Ischemic changes</arm_group_label>
    <description>Patients with ischemic changes in the brain diagnosed by MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ischemic changes</arm_group_label>
    <description>Patients without ischemic changes in the brain diagnosed by MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.</description>
    <arm_group_label>Ischemic changes</arm_group_label>
    <arm_group_label>No ischemic changes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples collection</intervention_name>
    <description>Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.</description>
    <arm_group_label>Ischemic changes</arm_group_label>
    <arm_group_label>No ischemic changes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neuropsychological tests</intervention_name>
    <description>Cognitive functions assessment</description>
    <arm_group_label>Ischemic changes</arm_group_label>
    <arm_group_label>No ischemic changes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 7th Navy Hospital in Gdansk, which had a brain MRI performed within the past
        4 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the ischemic changes in the brain (diagnosed by neurologist by MRI scans)

        Exclusion Criteria:

          -  no ischemic changes in the brain (diagnosed by neurologist by MRI scans)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Olek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gdansk University of Physical Education and Sport</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert A Olek, PhD</last_name>
    <phone>58 5547392</phone>
    <phone_ext>+48</phone_ext>
    <email>robol@awf.gda.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Physical Education and Sport</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-336</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gdansk University of Physical Education and Sport</investigator_affiliation>
    <investigator_full_name>Robert Olek</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>trimethylamine-N-oxide</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>cognitive functions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Leukoaraiosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

